| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $919,020 ) |
| | 2025 | 2025 | ENFUEGO THERAPEUTICS, INC. | 37 LINDA LEE CIR | PITTSBORO | NC | 27312-9815 | CHATHAM | USA | R44CA284932 | Ligand-Directed KRAS G12V Mutant-Specific Therapeutics | 001 | 3 | NIH | 9/3/2025 | $919,020 |
| | 2025 | 2023 | ENFUEGO THERAPEUTICS, INC. | 37 LINDA LEE CIR | PITTSBORO | NC | 27312-9815 | CHATHAM | USA | R44CA284932 | Ligand-Directed KRAS G12V Mutant-Specific Therapeutics | 000 | 1 | NIH | 2/28/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $919,020 ) |
| | 2024 | 2024 | ENFUEGO THERAPEUTICS, INC. | 37 LINDA LEE CIR | PITTSBORO | NC | 27312-9815 | CHATHAM | USA | R44CA284932 | Ligand-Directed KRAS G12V Mutant-Specific Therapeutics | 002 | 2 | NIH | 7/9/2024 | $919,020 |
| | 2024 | 2023 | ENFUEGO THERAPEUTICS, INC. | 37 LINDA LEE CIR | PITTSBORO | NC | 27312-9815 | CHATHAM | USA | R44CA284932 | Ligand-Directed KRAS G12V Mutant-Specific Therapeutics | 000 | 1 | NIH | 10/12/2023 | $0 |
| | 2024 | 2023 | ENFUEGO THERAPEUTICS, INC. | 37 LINDA LEE CIR | PITTSBORO | NC | 27312-9815 | CHATHAM | USA | R44CA284932 | Ligand-Directed KRAS G12V Mutant-Specific Therapeutics | 001 | 1 | NIH | 10/13/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $275,645 ) |
| | 2023 | 2023 | ENFUEGO THERAPEUTICS INC | 37 LINDA LEE CIR | PITTSBORO | NC | 27312-9815 | CHATHAM | USA | R44CA284932 | Ligand-Directed KRAS G12V Mutant-Specific Therapeutics | 001 | 1 | NIH | 7/26/2023 | $275,645 |
| | 2023 | 2023 | ENFUEGO THERAPEUTICS INC | 37 LINDA LEE CIR | PITTSBORO | NC | 27312-9815 | CHATHAM | USA | R44CA284932 | Ligand-Directed KRAS G12V Mutant-Specific Therapeutics | 000 | 1 | NIH | 7/5/2023 | $275,645 |
| | 2023 | 2023 | ENFUEGO THERAPEUTICS INC | 37 LINDA LEE CIR | PITTSBORO | NC | 27312-9815 | CHATHAM | USA | R44CA284932 | Ligand-Directed KRAS G12V Mutant-Specific Therapeutics | 001 | 1 | NIH | 7/26/2023 | -$275,645 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2020 | ENFUEGO THERAPEUTICS INC | 37 LINDA LEE CIR | PITTSBORO | NC | 27312-9815 | CHATHAM | USA | R41CA246848 | Development of EFTX-001 to target KRAS mutations in cancer | 000 | 1 | NIH | 7/25/2022 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $224,995 ) |
| | 2020 | 2020 | ENFUEGO THERAPEUTICS INC. | 37 LINDA LEE CIR | PITTSBORO | NC | 27312-9815 | CHATHAM | USA | R41CA246848 | Development of EFTX-001 to target KRAS mutations in cancer | 000 | 1 | NIH | 5/26/2020 | $224,995 |
| | 2020 | 2020 | ENFUEGO THERAPEUTICS INC. | 37 LINDA LEE CIR | PITTSBORO | NC | 27312-9815 | CHATHAM | USA | R41CA246848 | Development of EFTX-001 to target KRAS mutations in cancer | 001 | 1 | NIH | 7/7/2020 | $0 |
|
|
